Cancer of unknown primary patients with midline nodal distribution: Midway between poor and favourable prognosis?

Cancer Treatment Reviews

Volumn 37, Issue 2, 2011, Pages 120-126

  Pentheroudakis, George ^a   Stoyianni, Aikaterini ^a   Pavlidis, Nicholas ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Cancer of unknown primary site; Midline nodal; Prognosis; Therapy

Indexed keywords

BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CELL MARKER; CISPLATIN; ETOPOSIDE; IRINOTECAN; OXALIPLATIN; PLATINUM; TAXANE DERIVATIVE; TUMOR MARKER; VINCA ALKALOID;

ADENOCARCINOMA; ADULT; AGED; CANCER CELL; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CELL DIFFERENTIATION; COHORT ANALYSIS; DRUG RESPONSE; FEMALE; FITNESS; GERM CELL; HAZARD RATIO; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PREDICTION; PROGNOSIS; PUBLISHING; RETROSPECTIVE STUDY; REVIEW; SURVIVAL; SURVIVAL TIME; SYSTEMATIC REVIEW (TOPIC); TUMOR VOLUME; VISCERAL METASTASIS;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, UNKNOWN PRIMARY; NEUROENDOCRINE TUMORS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79151470216     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.06.003     Document Type: Review

References (24)

1. Pavlidis N., Briasoulis E., Hainsworth J., Greco F.A. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003, 39:1990-2005.
2. Pentheroudakis G., Briasoulis E., Karavassilis V., Fountzilas G., Xeros N., et al. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?. Acta Oncol 2005, 44:155-160.
3. Randen M., Rutqvist L.E., Johansson H. Cancer patients without a known primary: incidence and survival trends in Sweden 1960-2007. Acta Oncol 2009, 48(6):915-920.
4. Lazaridis G., Pentheroudakis G., Fountzilas G., Pavlidis N. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev 2008, 34:693-700.
5. Adenis A., Ferté C., Penel N. Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis. Invest New Drugs 2010 Apr, 28(2):178-184.
6. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer: I. The value of histologic grade in breast cancer-experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
7. Greco A., Vaughn W., Hainsworth J. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Inter Med 1986, 104:547-553.
8. Pavlidis N., Kosmidis P., Skarlos D., Briaosulis E., Beer M., et al. Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. Ann Oncol 1992, 3:631-634.
9. Hainsworth J., Johnson D., Greco A. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992, 10(6):912-922.
10. Abbruzzese J., Abbruzzese M., Hess K., Raber M., Lenzi R., et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994, 12(6):1272-1280.
11. Van der Gaast A., Verweij J., Planting A.S.T., Hop W.C.J., Stater G. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 1995, 13(7):1720-1725.
12. Lenzi R., Hess K., Abbruzzese M., Raber M., Ordonez R., et al. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients unknown-primary carcinoma?. J Clin Oncol 1997, 15(5):2056-2066.
13. Briasoulis E., Tsavaris N., Fountzilas G., Athanasiadis A., Kosmidis P., et al. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas on unknown primary site: a Hellenic Co-operative Oncology Group phase II study. Oncology 1998, 55:426-430.
14. Briasoulis E., Kalofonos H., Bafaloukos D., Samantas E., Fountzilas G., et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Co-operative Oncology Group study. J Clin Oncol 2000, 18(17):3101-3107.
15. Greco A., Burris H., Litchy S., Barton J., Bradof J., et al. Gemcitabine, carboplatin and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Network study. J Clin Oncol 2002, 20(6):1651-1656.
16. Pentheroudakis G., Briasoulis E., Kalofonos H., Fountzilas G., Economopoulos T., et al. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma on unknown primary: a multicentre Hellenic Co-operative Oncology Group study. Acta Oncol 2008, 47:1148-1155.
17. Hartmann J.T., Nichols C.R., Droz J.P., Horwich A., Gerl A., et al. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol 2002, 13:1017-1028.
18. Pectasides D., Aravantinos G., Visvikis A., Bakoyiannis Ch., Halikia A., et al. Platinum-based chemotherapy of primary extragonadal germ cell tumors: Hellenic Co-operative Oncology Group experience. Oncology 1999, 57:1-9.
19. Shah T., Srirajaskanthan R., Bhogal M., Toubanakis C., Meyer T., Noonan A., et al. a-Fetoprotein and human chorionic gonadotrophin-b as prognostic markers in neuroendocrine tumor patients. Br J Cancer 2008, 99:72-77.
20. Lloyd R.V. Practical markers used in the differential diagnosis of endocrine tumors. Endocr Pathol 2003, 14:293-301.
21. Suster S., Moran C.A. Neuroendocrine neoplasms of the mediastinum. Am J Clin Pathol 2001, 115(Suppl.):S17-S27. (Review).
22. Currow D.C., Findlay M., Cox K., Harnett P.R. Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy. Eur J Cancer 1996, 32A(13):2357-2359.
23. Varadhachary G.R., Talantov D., Raber M.N., Meng C., Hess K.R., Jatkoe T., et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008, 26(27):4442-4448.
24. Horlings H.M., van Laar R.K., Kerst J.M., Helgason H.H., Wesseling J., van der Hoeven J.J., et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008, 26(27):4435-4441.